1. Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients?
    Umberto Maggiore et al, 2021, Transplant International CrossRef
  2. Pharmacokinetics of alectinib and its metabolite M4 in a patient with advanced lung adenocarcinoma undergoing hemodialysis: A case report
    Ji Eun Park et al, 2022, Thoracic Cancer CrossRef
  3. Brigatinib pharmacokinetics in patients with chronic hepatic impairment
    Michael J. Hanley et al, 2023, Investigational New Drugs CrossRef
  4. Validation of an LC-MS/MS assay for rapid and simultaneous quantification of 21 kinase inhibitors in human plasma and serum for therapeutic drug monitoring
    Zaid N. Al Shirity et al, 2023, Journal of Chromatography B CrossRef
  5. Renal adverse reactions of tyrosine kinase inhibitors in the treatment of tumours: A Bayesian network meta-analysis
    Ying Xiong et al, 2022, Frontiers in Pharmacology CrossRef
  6. Clinical use of lenvatinib in patients with previous renal and/or hepatic impairment and radioiodine‐refractory differentiated thyroid cancer
    Javier Martínez‐Trufero, 2022, Cancer Medicine CrossRef
  7. Dose Adjustment of Poly (ADP‑Ribose) Polymerase Inhibitors in Patients with Hepatic or Renal Impairment
    Dehua Zhao et al, 2022, Drug Design, Development and Therapy CrossRef
  8. Cancer Risk and Mortality in Patients With Kidney Disease: A Population-Based Cohort Study
    Abhijat Kitchlu et al, 2022, American Journal of Kidney Diseases CrossRef